百奧泰(688177.SH):針對腫瘤免疫檢查點、腫瘤靶點、腫瘤微環境的新型抗體項目已經完成臨牀前研究
格隆匯6月13日丨百奧泰(688177.SH)在互動平台表示,在創新藥領域,公司自主開發的用於心血管疾病的1類化學藥品貝塔寧®(枸櫞酸倍維巴肽注射液)已獲得國家藥監局上市批准;專門設計用於眼底病變治療的單克隆抗體BAT5906已完成III期臨牀研究;ADC技術平台下已有4款產品處於臨牀階段,公司在2025年美國臨牀腫瘤學會(ASCO)年會上展示了一系列腫瘤管線臨牀進展或階段性數據,包括BAT8006 (FRα ADC)、BAT8008(Trop-2 ADC)、BAT8010(HER2 ADC)聯合ADCC增強型BAT1006(HER2單抗)、BAT1308(PD-1)聯合化療±貝伐珠單抗,詳情請見公司官網發佈的相關會議摘要。同時,公司新一代靶向PD1,HER2,CTLA-4,CD20,OX40抗體和新一代雙特異抗體BAT7104(PD-L1/CD47)、雙特異抗體BAT7111(PD-1/4-1BB)、雙功能抗體融合蛋白BAT7205(PD-L1/IL-15)已經逐漸逐個進入臨牀研究;更多的針對腫瘤免疫檢查點、腫瘤靶點、腫瘤微環境的新型抗體項目已經完成臨牀前研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.